Edition:
United States

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

1.24USD
23 Feb 2018
Change (% chg)

$0.06 (+5.08%)
Prev Close
$1.18
Open
$1.19
Day's High
$1.25
Day's Low
$1.16
Volume
24,983
Avg. Vol
62,509
52-wk High
$5.32
52-wk Low
$1.16

Select another date:

Fri, Feb 16 2018

BRIEF-Lipocine Announces Settlement Of Securities Class Action Lawsuit

* LIPOCINE ANNOUNCES SETTLEMENT OF SECURITIES CLASS ACTION LAWSUIT

BRIEF-Lipocine Announces $10 Mln Loan And Security Agreement With Silicon Valley Bank

* LIPOCINE ANNOUNCES $10 MILLION LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage:

BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando

* LIPOCINE - FDA'S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO'S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO

BRIEF-Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement

* LIPOCINE INC SAYS ON JAN 5, CO, UNIT, SILICON VALLEY BANK ("SVB") ENTERED INTO A LOAN AND SECURITY AGREEMENT -SEC FILING

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged

BRIEF-Lipocine Inc Q3 loss per share $0.22

* Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017

BRIEF-Lipocine says FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018

* Lipocine -‍ announced FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018 to discuss NDA for Tlando​

BRIEF-Lipocine Inc files for mixed shelf of up to $150 million

* Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2zlVhiU) Further company coverage:

BRIEF-Lipocine - ‍PTAB of USPTO issued a motions decision in interference case between Clarus Therapeutics and Lipocine Inc​

* Lipocine - ‍ PTAB of USPTO issued a motions decision based on each party's motions in interference case between Clarus Therapeutics and Lipocine Inc​

BRIEF-Lipocine announces FDA Advisory Committee meeting for TLANDO

* Lipocine Inc - advisory committee meeting date has not been finalized but will occur prior to PDUFA goal date of February 8, 2018 Source text for Eikon: Further company coverage:

Select another date: